Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential
Ellen Gorman, Jonathan Millar, Danny McAuley, Cecilia O’Kane
Abstract
: MSC products present considerable therapeutic promise for ARDS and sepsis. Preclinical investigations report significant benefits and early phase clinical studies have not highlighted safety concerns. Optimization of MSC function in preclinical models of ARDS and sepsis has enhanced their beneficial effects. MSC-derived products, as cell-free alternatives, may provide further advantages in this field. These strategies present opportunity for the clinical development of MSCs and MSC-derived products with enhanced therapeutic efficacy.
Topics & Concepts
ARDSMedicineMesenchymal stem cellAcute respiratory distressSepsisIntensive care medicineStromal cellCoronavirus disease 2019 (COVID-19)ImmunologyLungInternal medicinePathologyDiseaseInfectious disease (medical specialty)Mesenchymal stem cell researchRespiratory Support and MechanismsHydrogen's biological and therapeutic effects